Lower copayments benefit patient and payer

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.665, 2012-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Copayments could be costly for public health

Inpharma, Vol. 1, Iss. 1623, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Patient Benefit-Risk Preferences for Targeted Agents in the Treatment of Renal Cell Carcinoma

By Mohamed Ateesha F.

PharmacoEconomics, Vol. 29, Iss. 11, 2011-11 ,pp. : 977-988

Adis International

Access to resources Recommend Favorite

Copayments and caps could be creating false economy

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 547, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

How can the emerging patient-centric health records lower costs in pharmacogenomics?

By Shabo (Shvo) Amnon

Pharmacogenomics, Vol. 8, Iss. 5, 2007-05 ,pp. : 507-511

Future Medicine

Access to resources Recommend Favorite

Payer perspectives on pharmacogenomics testing and drug development

By Epstein Robert S Frueh Felix W Geren Dawn Hummer Doris McKibbin Scott O’’Connor Susan Randhawa Gurvaneet Zelman Benjamin

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 149-151

Future Medicine

Access to resources Recommend Favorite